Skip to content
i2E
  • Programs
    • For Startups
      • E3
      • Bridge2
      • OCN
    • For Students
      • Entrepreneur’s Cup
    • For Corporations
    • For Investors
  • Client Portfolio
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Events
  • Contact
  • Media
  • Programs
    • For Startups
      • E3
      • Bridge2
      • OCN
    • For Students
      • Entrepreneur’s Cup
    • For Corporations
    • For Investors
  • Client Portfolio
  • About
    • Our Values
    • Meet Our Team
    • Board of Directors
    • Corporate Partners
  • Events
  • Contact
  • Media
Search

DormaTarg working to make impact on cancer

Get in Touch

By Scott Meacham
Copyright © 2014, The Oklahoma Publishing Company

Oklahoma is building a reputation nationwide as a place where discoveries in bioscience lead to groundbreaking solutions that can have a real impact on people’s lives.

One exciting example is DormaTarg, an Oklahoma-based firm that is developing therapeutics to deal with one of the toughest challenges in fighting cancer — inhibiting the recurrence in metastasis-prone cancers.

“We have a drug that we believe targets dormant cells before they reactivate and can prevent cancer from metastasizing — going from a primary to a secondary site,” said Michael Ihnat, DormaTarg’s director of drug development.

When tumors travel from the point of origin to some other part of the body, they frequently go dormant; they are hard to find and identify, even with current technology.

Further, even though the tumors aren’t actively growing, they are waiting until certain conditions allow them to reactivate, after which the cancer is likely to be stronger and more vicious than the primary tumor was.

The American Cancer Society reports that upwards of 90 percent of all cancer deaths resulting from cancer are attributable to metastasis.

The initial application of DormaTarg’s agent is for triple negative breast cancer (TNBC), which is so named because this metastasis-prone cancer lacks three essential targets for current therapy. TNBC accounts for about 15 percent to 25 percent of all breast cancer cases.

DormaTarg screened more than 15,000 compounds to develop the DT300 series of molecules. DT330 has prevented reactivation of metastatic cancer cells in pre-clinical trials and has been shown to be relatively nontoxic, water soluble, and compatible with current therapies.

This amazing science has the potential to help thousands of TNBC patients and eventually patients with other metastatic cancers as well.

But that’s just part of the DormaTarg story. The greatest science in the world can’t help patients until it reaches the marketplace.

The DormaTarg team of cancer specialists and entrepreneurs, with more than 40 years of experience in cancer research and drug development, is meeting the milestones that remove risk and prove efficacy.

DormaTarg has been primarily funded through the Small Business Innovation Research program and other sources of nondilutive capital, of more than $3 million, most of which came from the National Cancer Institute.

The firm has strategic partnerships with some of the best regulatory consultants, formulation experts, and intellectual property attorneys in the industry.

“TNBC is our best entry point to prove efficacy,” Ihnat said. “Our end game is to make a real difference on the aspect of cancer that kills millions of patients every year.”

Oklahoma’s bioscience sector’s economic activity already exceeds $6.7 billion with a return on the state’s investment through the Oklahoma Center for the Advancement of Science and Technology of better than 20-to-1.

It’s great to think that the relatively small investments we are making in biotechnology in Oklahoma may have such a fundamental, lifesaving impact on people around the globe someday.

Scott Meacham is president and CEO of i2E Inc., a nonprofit corporation that mentors many of the state’s technology-based startup companies. i2E receives state appropriations from the Oklahoma Center for the Advancement of Science and Technology. Contact Meacham at [email protected].

Did You Know? Bioscience businesses in Oklahoma support more than 51,000 Oklahoma jobs and annual revenues of more than $4.1 billion.

Read it at newsok.com

 

More News

Loading...
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
04.25.25

Oklahoma Collegiate Entrepreneurs Take Home Over $167K at Entrepreneur’s Cup

Read more
Blog, Featured, News
12.16.24

MidAmerica and i2E Announce Award Winners

Read more
Blog, Featured, News
11.21.24

i2E & Plains Ventures Surpasses $100M Milestone in Total Investments

Read more
Blog
09.30.24

i2E Receives 2024 Excellence in Economic Development Award from IEDC

Read more
Blog
06.18.24

Bridge2 Demo Day Returns, Highlighting Promising Oklahoma Startups

Read more
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
05.13.24

Student Entrepreneurs Triumph at 20th Anniversary Entrepreneur’s Cup, Winning $158,000 in Prizes

Read more
Default Featured Image
Blog, Entrepreneur's Cup News
04.24.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Jessica Kinsey

Read more
Default Featured Image
Blog, Entrepreneur's Cup News
04.23.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Nathan Fountain

Read more
Default Featured Image
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
04.23.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – Srijita Ghosh

Read more
Default Featured Image
Blog, Entrepreneur's Cup Featured, Entrepreneur's Cup News
04.18.24

Beyond the Cup: Tracking Success Stories from the Entrepreneur’s Cup Series – MaxQ

Read more
Blog, i2E
01.30.24

i2E Celebrates Success of Inaugural Bridge2 Demo Day

Read more
Blog, i2E, News
12.18.23

i2E and MidAmerica Industrial Park announce award winners for high school entrepreneurship program

Read more
i2E

Oklahoma City Office

201 Robert S Kerr Ave, Suite 600
Oklahoma City, OK 73102
+1 (405) 235.2305

Tulsa Office

12 N. Cheyenne Ave, Suite 112
Tulsa, OK 74103
+1 (918) 582.5592

  • Client Portfolio
  • About Us
  • Media
  • Events
  • Contact
  • Resources
  • Funding
  • Venture Advisory

© 2025 i2E Privacy Policy

Follow us:

Linkedin Twitter Facebook Instagram Youtube

Programs

  • For Startups
    • E3
    • Bridge2
    • OCN
  • For Students
    • Entrepreneur’s Cup
  • For Corporations
  • For Investors
  • For Startups
    • E3
    • Bridge2
    • OCN
  • For Students
    • Entrepreneur’s Cup
  • For Corporations
  • For Investors
  • Client Portfolio

Services

  • Access to Funding
  • Venture Advisory Services
  • Events
  • Contact
  • About
  • Our Values
  • Our Team
  • Board of Directors
  • Corporate Partners
  • Media
i2E